Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling